Atazanavir/ritonavir
Atazanavir/ritonavir (ATV/r) is a combination medication used in the treatment of HIV/AIDS.[1] It combines atazanavir and ritonavir.[1] It may be used instead of lopinavir/ritonavir.[2] It is taken by mouth.[1]
Combination of | |
---|---|
Atazanavir | Protease inhibitor |
Ritonavir | Protease inhibitor (pharmacokinetic booster) |
Clinical data | |
Other names | Anzavir-R, ritonavir/atazanavir[1] |
Routes of administration | By mouth[1] |
ATC code |
Side effects are generally minimal.[2] They may include abdominal pain, diarrhea, yellowish skin, muscle pains, and headache.[2] Greater care should be taken in people with underlying liver problems.[2] Use in pregnancy appears to be safe.[3] In the combination atazanavir functions as a protease inhibitor and ritonavir functions to increase levels of atazanavir.[2]
The combination was approved for use in India in 2012 and is pending approval in the US as of 2017.[1] It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.[4] The average cost per year is 281 USD in the developing world as of 2012.[2]
References
- "Atazanavir/ritonavir - Mylan Laboratories - AdisInsight". adisinsight.springer.com. Retrieved 29 June 2017.
- "WHO Model List of Essential Medicines Application" (PDF). WHO. Retrieved 29 June 2017.
- "Atazanavir/Ritonavir in Pregnancy". hivinsite.ucsf.edu. Retrieved 10 December 2017.
- "WHO Model List of Essential Medicines (20th List)" (PDF). World Health Organization. March 2017. Retrieved 29 June 2017.